Aktuellt
SENASTE
Ascelia’s leading SPARKLE study has recruited 71 (out of 80) patients, as announced earlier, and the study is on track for completion by the end of February or in March at the latest. SPARKLE results are expected by mid-2023. SGA is in line with expectations, and R&D is slightly ahead of expectations, balanced by a lower operational cash burn (SEK 29m) due to higher accounts payables. The cash balance is also above expectations in Q4 at SEK 148m. We expect a neutral share price reaction from Ascelian’s Q4 result.
LÄS MER
